PAID ADVERTISEMENT
Did you know that iron deficiency in HF
- Can occur with or without anemia
- Is associated with poor QOL, reduced exercise capacity, increased risk for HF hospitalization and death
- Isn’t treated effectively with oral iron
- Is treatable with guideline-recommended IV iron to improve outcomes!
Sunday, November 12, 2023
Dinner and Registration: 6:30 pm – 7:00 pm ET
Symposium: 7:00 pm – 8:30 pm ET
Philadelphia Marriott Downtown Ballroom: Salon H-J, 5th Level
1201 Market Street, Philadelphia, PA
Faculty:
Robert Mentz, MD (Chair)
Nancy M. Albert, PhD, CCNS, CHFN, CCRN, NE-BC
Stefan D. Anker, MD, PhD
Katherine E. Di Palo, PharmD, MBA, MS
Adrian F. Hernandez, MD, MHS
Educational Objectives:
- Describe the pathophysiology of iron deficiency in HF
- Discuss the deleterious impact of comorbid iron deficiency and HF, irrespective of concomitant anemia
- Identify who and when to screen for iron deficiency
- Interpret data with IV therapy for iron deficiency in HF patients
Experts will explain the role of hepcidin in hyperinflammatory states (such as HF) and subsequent implications on iron supplementation approaches. The prognosis of comorbid iron deficiency and HF will be described, and appropriate, timely patient screening and diagnostic testing of serum ferritin and transferrin saturation (TSAT) will be emphasized based on expert-generated algorithms. A multidisciplinary panel will translate clinical evidence with IV iron therapy into “real-world” clinical practice.
This event is not part of the official Scientific Sessions 2023 as planned by the AHA Committee on Scientific Sessions Program.
